Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | RAB9A | P51151 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10999006 | 0.89 | TERT (0.51) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9704277 | 0.84 | MAPT (0.44) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10999725 | 0.84 | NPC1 (0.51) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3229472 | 0.84 | NPC1 (0.63) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9704263 | 0.83 | RAB9A (0.57) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9655586 | 0.82 | HPGD (0.53) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3221922 | 0.82 | NPC1 (0.73) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11004722 | 0.81 | HTT (0.53) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL24458194 | 0.81 | MAPT (0.55) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL11003572 | 0.80 | NPC1 (0.61) | NPC1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| US-4533612-A | 2-SUBSTITUTED BENZOTRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1985-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | NPC1 2697/4885MAPT 2870/4885RAB9A 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.